Morgan Stanley analyst Tejas Savant raised the firm’s price target on Veracyte (VCYT) to $40 from $28 and keeps an Underweight rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- NCCN guidelines incrementally favorable for Veracyte’s Decipher, says Guggenheim
- Veracyte Inc. Reports Robust Q3 Earnings Performance
- Veracyte rises 21.4%
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
- Veracyte rises 26.4%